Compare ING Groep NV (ING) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Zoetis Inc — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: ING Groep NV is far larger — about 3.1× Zoetis Inc's market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Zoetis Inc for 70 Days on average.
| ING | ZTS | |
|---|---|---|
Market Cap | $93.76B | $30.20B |
Volume | 4,620,220 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $37.27 | $147.53 |
52-Week Low | $23.66 | $69.09 |
Typical Hold Time | 94 Days | 70 Days |
Enterprise Value | $236.48B | $37.76B |
Dividend Yield | 3.95% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.43, down 1.44% with a bearish technical outlook. The company shows strong fundamentals with consistent earnings beats, a 28.34% net margin, and positive analyst sentiment (64.71% buy ratings). Recent news highlights management's raised ROE target to 16% for 2027 and upgraded revenue guidance, though cash flow trends remain negative.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include persistent negative cash flows and regulatory scrutiny in Australia. The stock presents value with a reasonable P/E of 12.86, supported by dividend payments and institutional confidence.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
